[BSTEAD] YoY Cumulative Quarter Result on 31-Mar-2015 [#1]

Stock
[BSTEAD] BOUSTEAD HOLDINGS BHD
Announcement Date
25-May-2015
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2015
Quarter
31-Mar-2015 [#1]
Profit Trend
QoQ- -99.98%
YoY- -99.85%
Quarter Report
Latest QR
Upcoming QR
BSTEAD's Result
BSTEAD's Financial Summary
View:
Show?
Cumulative Result
31/03/18 31/03/17 31/03/16 31/03/15 31/03/14 31/03/13 31/03/12 CAGR
Revenue 2,245,000 2,375,200 1,856,700 1,892,300 2,499,800 2,531,100 2,328,000 -0.60%
PBT 70,300 71,600 36,300 69,500 133,300 174,900 222,900 -17.48%
Tax -32,200 -30,700 -26,800 -26,400 -41,900 -40,800 -34,200 -0.99%
NP 38,100 40,900 9,500 43,100 91,400 134,100 188,700 -23.39%
-
NP to SH 6,100 4,200 -21,500 100 66,700 99,900 144,600 -40.98%
-
Tax Rate 45.80% 42.88% 73.83% 37.99% 31.43% 23.33% 15.34% -
Total Cost 2,206,900 2,334,300 1,847,200 1,849,200 2,408,400 2,397,000 2,139,300 0.51%
-
Net Worth 6,141,809 5,635,059 5,705,769 5,659,999 5,222,248 4,684,751 4,582,102 5.00%
Dividend
31/03/18 31/03/17 31/03/16 31/03/15 31/03/14 31/03/13 31/03/12 CAGR
Div 50,675 50,675 51,682 50,000 77,558 77,562 77,575 -6.84%
Div Payout % 830.74% 1,206.55% 0.00% 50,000.00% 116.28% 77.64% 53.65% -
Equity
31/03/18 31/03/17 31/03/16 31/03/15 31/03/14 31/03/13 31/03/12 CAGR
Net Worth 6,141,809 5,635,059 5,705,769 5,659,999 5,222,248 4,684,751 4,582,102 5.00%
NOSH 2,027,000 2,027,000 1,033,653 1,000,000 1,034,108 1,034,161 1,034,334 11.86%
Ratio Analysis
31/03/18 31/03/17 31/03/16 31/03/15 31/03/14 31/03/13 31/03/12 CAGR
NP Margin 1.70% 1.72% 0.51% 2.28% 3.66% 5.30% 8.11% -
ROE 0.10% 0.07% -0.38% 0.00% 1.28% 2.13% 3.16% -
Per Share
31/03/18 31/03/17 31/03/16 31/03/15 31/03/14 31/03/13 31/03/12 CAGR
RPS 110.75 117.18 179.62 189.23 241.73 244.75 225.07 -11.14%
EPS 0.30 0.21 -2.08 0.01 6.45 9.66 13.98 -47.26%
DPS 2.50 2.50 5.00 5.00 7.50 7.50 7.50 -16.72%
NAPS 3.03 2.78 5.52 5.66 5.05 4.53 4.43 -6.13%
Adjusted Per Share Value based on latest NOSH - 1,000,000
31/03/18 31/03/17 31/03/16 31/03/15 31/03/14 31/03/13 31/03/12 CAGR
RPS 110.75 117.18 91.60 93.35 123.33 124.87 114.85 -0.60%
EPS 0.30 0.21 -1.06 0.00 3.29 4.93 7.13 -41.01%
DPS 2.50 2.50 2.55 2.47 3.83 3.83 3.83 -6.85%
NAPS 3.03 2.78 2.8149 2.7923 2.5763 2.3112 2.2605 5.00%
Price Multiplier on Financial Quarter End Date
31/03/18 31/03/17 31/03/16 31/03/15 31/03/14 31/03/13 31/03/12 CAGR
Date 30/03/18 31/03/17 31/03/16 31/03/15 31/03/14 29/03/13 30/03/12 -
Price 2.54 2.77 3.93 4.60 5.42 5.13 5.43 -
P/RPS 2.29 2.36 2.19 2.43 2.24 2.10 2.41 -0.84%
P/EPS 844.03 -1,403.70 -188.94 46,000.00 84.03 53.11 38.84 67.01%
EY 0.12 -0.07 -0.53 0.00 1.19 1.88 2.57 -39.97%
DY 0.98 0.90 1.27 1.09 1.38 1.46 1.38 -5.54%
P/NAPS 0.84 1.39 0.71 0.81 1.07 1.13 1.23 -6.15%
Price Multiplier on Announcement Date
31/03/18 31/03/17 31/03/16 31/03/15 31/03/14 31/03/13 31/03/12 CAGR
Date 31/05/18 29/05/17 25/05/16 25/05/15 26/05/14 22/05/13 28/05/12 -
Price 2.42 2.60 2.84 4.40 5.36 5.39 5.08 -
P/RPS 2.19 2.22 1.58 2.33 2.22 2.20 2.26 -0.52%
P/EPS 804.15 -1,317.55 -136.54 44,000.00 83.10 55.80 36.34 67.51%
EY 0.12 -0.08 -0.73 0.00 1.20 1.79 2.75 -40.65%
DY 1.03 0.96 1.76 1.14 1.40 1.39 1.48 -5.85%
P/NAPS 0.80 1.30 0.51 0.78 1.06 1.19 1.15 -5.86%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment